SEARCH:   Advanced

Blood, 1 October 2008, Vol. 112, No. 7, pp. 2681-2686. Prepublished online as a Blood First Edition Paper on July 7, 2008; DOI 10.1182/blood-2008-05-153700. This Article Full Text (PDF) All Versions of this Article: blood-2008-05-153700v1 112/7/2681    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Scott, B. L. Articles by Deeg, H J. Search for Related Content PubMed PubMed Citation Articles by Scott, B. L. Articles by Deeg, H J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 5, 2008 Accepted June 22, 2008 Validation of a flow cytometric scoring system as a prognostic indicator for post-transplant outcome in patients with MDS Bart L. Scott*, Denise A Wells, Michael R Loken, David Myerson, Wendy M. Leisenring, and H Joachim Deeg Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States Hematologics Inc., Seattle, WA, United States Clinical Research Division, University of Washington School of Medicine, Seattle, WA, United States * Corresponding author; email: bscott{at}fhcrc.org. A prospective cohort was analyzed to confirm the utility of a flow cytometric score system (FCSS) in patients with myelodysplastic syndrome (MDS). One hundred fifty-two patients receiving a first stem cell transplant had marrow cells prospectively analyzed to calculate the FCSS score. The FCSS scores were retrospectively compared to patient outcomes in both univariate and multivariate models. The cumulative incidence of post-transplant relapse at 3 years was 15%, 10%, and 36% for patients with mild, moderate, and severe FCSS scores, respectively, with the hazard for relapse of 2.8 (p=0.02) for severe scores in comparison to patients with mild or normal FCSS scores. In multivariate analyses, the FCSS score was associated with relapse even after accounting for IPSS score or for marrow myeloblast percentage. Among patients with Intermediate-1 risk by IPSS, severe FCSS scores were associated with an increased hazard of relapse (HR=3.8; p=0.02) compared to patients with normal/mild/moderate FCSS scores. Among patients with less than 5% marrow myeloblasts, myeloblast dyspoiesis was associated with an increased hazard of relapse (HR=3.7; p=0.02).This analysis confirmed that FCSS scores are predictive of post-transplant outcomes in patients with MDS even after adjusting for risk factors such as marrow myeloblast percentage and IPSS score. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Cazzola Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome Haematologica, August 1, 2009; 94(8): 1041 - 1043. [Full Text] [PDF] A. A. van de Loosdrecht, C. Alhan, M. C. Bene, M. G. Della Porta, A. M. Drager, J. Feuillard, P. Font, U. Germing, D. Haase, C. H. Homburg, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes Haematologica, August 1, 2009; 94(8): 1124 - 1134. [Abstract] [Full Text] [PDF] H. J. Deeg Allogeneic Hematopoietic Cell Transplantation in Older Patients with Myelodysplastic Syndrome ASCO Educational Book, January 1, 2009; 2009(1): 420 - 424. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020